Forge Biologics, Inc. news
Eikonoklastes Therapeutics, a preclinical biotech company developing treatments for today’s most challenging diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Forge will provide adeno-associated viral (AAV) process dev
- Clinical data demonstrating initial safety and efficacy from the RESKUE trial are being presented by Chief Medical Officer Maria Escolar, M.D., at the 29th Congress of European Society of Gene & Cell Therapy (ESGCT), October 11-14, 2022
- Subjects treated with FBX-101 have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter myelination and normalization of motor development in two children 90
Ray Therapeutics, a biotechnology company developing optogenetic gene therapies for patients with retinal degenerative conditions, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced further collaboration for their manufacturing partnership to include clinical stage plasmid DNA production to support Ray Therapeutics’ lead optogenetics gene therapy program, RTx-015, in clinical trials for patients with retinitis pigmentosa.
F
Myrtelle Inc., (Myrtelle), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases, and Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced a manufacturing partnership that will advance Myrtelle’s novel gene therapy for monogenic hearing loss, Myr-201, into clinical trials for patients with autosomal recessive deafness 8 (DFNB8).
Forge will provide research-grade
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that company leadership members will be making presentations and taking one-on-one meetings at three upcoming investor relations conferences.
Jefferies Cell & Genetic Medicine Summit
Friday, September 30, 10:00-10:25 a.m. ET
Presenter: Christina Perry, Senior Vice President and Head, Finance & Investor Relations
Webcast Link: <
- Enables gene therapy clients to accelerate AAV manufacturing with seamless incorporation into the Company’s HEK 293 platform suspension process with access to end-to-end capabilities
- New offerings of Research-Grade and GMP-Pathway expedite Phase 1/2 clinical trial timelines, with GMP-Grade available in 2023
- Data to support Company’s plasmid production is being presented at BioProcess International East this week
- Total capital raised of $330 million since the Company’s launch in 2020
- Financing expands planned usage of Company’s 20 cGMP suites containing multiple 50L, 500L, 1,000L and 5,000L bioreactors for research-to-commercial gene therapy manufacturing
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has raised $90 million in a Series C financing, bringing its total fun
Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that Christina Perry, Senior Vice President of Finance & Investor Relations, will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, in New York, NY. Concurrently, Forge will host one-on-one meetings with interested investors.
Forge’s presentation is expected to begin at 10:00 a.m. ET. A live webc
- FBX-101 clinical data demonstrating safety and initial efficacy from the RESKUE trial is being presented at the 2022 Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
- FBX-101 is a systemic AAV gene therapy following unrelated cord blood transplantation (“UCBT”) and has been well tolerated through Day 180
- FBX-101 significantly increased GALC enzyme activity in leukocytes and patient exhibited improved moto